Literature DB >> 19901168

Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

Bryn M Burkholder1, Benjamin Osborne, Michael J Loguidice, Esther Bisker, Teresa C Frohman, Amy Conger, John N Ratchford, Christina Warner, Clyde E Markowitz, Dina A Jacobs, Steven L Galetta, Gary R Cutter, Maureen G Maguire, Peter A Calabresi, Laura J Balcer, Elliot M Frohman.   

Abstract

BACKGROUND: Inner (area adjacent to the fovea) and outer regions of the macula differ with respect to relative thicknesses of the ganglion cell layer (neurons) vs retinal nerve fiber layer (RNFL; axons).
OBJECTIVE: To determine how inner vs outer macular volumes relate to peripapillary RNFL thickness and visual function in multiple sclerosis (MS) and to examine how these patterns differ among eyes with vs without a history of acute optic neuritis (ON).
DESIGN: Study using cross-sectional optical coherence tomography.
SETTING: Three academic tertiary care MS centers. PARTICIPANTS: Patients with MS, diagnosed by standard criteria, and disease-free control participants. MAIN OUTCOME MEASURES: Optical coherence tomography was used to measure macular volumes and RNFL thickness. Visual function was assessed using low-contrast letter acuity and high-contrast visual acuity (Early Treatment Diabetic Retinopathy Study charts).
RESULTS: Among eyes of patients with MS (n = 1058 eyes of 530 patients), reduced macular volumes were associated with peripapillary RNFL thinning; 10-microm differences in RNFL thickness (9.6% of thickness in control participants without disease) corresponded to 0.20-mm(3) reductions in total macular volume (2.9% of volume in control participants without disease, P < .001). This relation was similar for eyes of MS patients with and without a history of ON. Although peripapillary RNFL thinning was more strongly associated with decrements in outer compared with inner macular volumes, correlations with inner macular volume were significant (r = 0.58, P < .001) and of slightly greater magnitude for eyes of MS patients with a history of ON vs eyes of MS patients without a history of ON (r = 0.61 vs r = 0.50). Lower (worse) visual function scores were associated with reduced total, inner, and outer macular volumes. However, accounting for peripapillary RNFL thickness, the relation between vision and inner macular volume remained significant and unchanged in magnitude, suggesting that this region contains retinal structures separate from RNFL axons that are important to vision.
CONCLUSIONS: Analogous to studies of gray matter in MS, these data provide evidence that reductions of volume in the macula (approximately 34% neuronal cells by average thickness) accompany RNFL axonal loss. Peripapillary RNFL thinning and inner macular volume loss are less strongly linked in eyes of MS patients without a history of ON than in eyes of MS patients with a history of ON, suggesting alternative mechanisms for neuronal cell loss. Longitudinal studies with segmentation of retinal layers will further explore the relation and timing of ganglion cell degeneration and RNFL thinning in MS.

Entities:  

Mesh:

Year:  2009        PMID: 19901168     DOI: 10.1001/archneurol.2009.230

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  74 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.

Authors:  Stephanie B Syc; Shiv Saidha; Scott D Newsome; John N Ratchford; Michael Levy; E'tona Ford; Ciprian M Crainiceanu; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Elliot M Frohman; Peter A Calabresi
Journal:  Brain       Date:  2011-10-17       Impact factor: 13.501

3.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

4.  Retinal Tissue Perfusion in Patients with Multiple Sclerosis.

Authors:  Yi Liu; Silvia Delgado; Hong Jiang; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovana Rosa Gameiro; Jianhua Wang
Journal:  Curr Eye Res       Date:  2019-05-15       Impact factor: 2.424

5.  Ganglion cell loss in relation to visual disability in multiple sclerosis.

Authors:  Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer
Journal:  Ophthalmology       Date:  2012-02-23       Impact factor: 12.079

6.  Optical coherence tomography: clinical applications in medical practice.

Authors:  Abdullah Al-Mujaini; Upender K Wali; Sitara Azeem
Journal:  Oman Med J       Date:  2013-03

7.  Relationship between Structural and Functional Assessment of the Visual System in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients.

Authors:  Nergiz Huseyinoglu; Metin Ekinci; Serkan Ozben; Cagatay Buyukuysal
Journal:  Neuroophthalmology       Date:  2014-01-28

8.  Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Authors:  Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon
Journal:  Neurology       Date:  2019-04-10       Impact factor: 9.910

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 10.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.